‘Otc Pharmaceutical Market Set To Grow To $183bn By 2022’ Says Visiongain Report

13 August 2018
Pharma

Visiongain has launched a new pharma report Anti- Global OTC Pharmaceutical Market Forecast 2017-2027: Cough, Cold and Allergy, Analgesics, Gastrointestinal, Dermatology, Eye Care, Smoking Cessation Aids, Others

The potential of the OTC pharmaceutical market remains significant and it is a growing segment in the largely stagnant overall pharmaceutical market. In the face of looming patent expiry and falling R&D productivity, the consumer healthcare and OTC business offers distinct advantages to pharmaceutical companies looking to create a diverse portfolio of businesses that achieves sustained revenue growth over the next ten years.

The lead analyst of the report commented “The growth of the OTC Pharmaceutical market will be driven by ageing demographic, cost pressures on healthcare providers, liberalisation of regulatory requirements, shifting cultural practices towards self-medication, and the continued switching of drugs from prescription-only to OTC.
Competition from private-label brands, regulatory concerns over OTC switching and the effective marketing of products via the Internet and social media are some of the challenges that OTC manufacturers and brands will need to address in the future.”

Leading companies featured in the report include Bayer AG, GlaxoSmithKline (GSK) Consumer Care, Perrigo Company PLC, Johnson & Johnson, Daiichi Sankyo Co., Ltd, Pfizer Inc., Procter & Gamble, Sanofi S.A, Reckitt Benckiser Group PLC, Cipla, Inc.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Ophthalmic Drugs market set to grow to $33bn by 2024” says new Visiongain report

The market for ophthalmic drugs is a growing one.

17 June 2019

Read

“Generic Drugs market set to grow to $424bn by 2024” says new Visiongain report

Visiongain believes the market will see more traditional pharma companies beginning to embrace the generic business in order to take advantage of higher growth rates in this area.

14 June 2019

Read

“Global Precision Cancer Diagnostic Tests market set to grow to $21.3bn by 2024” says new Visiongain report

The market players are increasingly focusing on precision therapies where drug and precision tests are developed simultaneously.

06 June 2019

Read

“Global Antifungal Drugs market set to grow to $17bn by 2024” says new Visiongain report

Market penetration and adoption of new technologies entering the market for antifungal drugs will be crucial for market growth.

04 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever